Morphological Meibomian Glands Changes in Glaucoma Patients with Chronic Topical Therapy | ASCRS
Morphological Meibomian Glands Changes in Glaucoma Patients with Chronic Topical Therapy
May 2019
Meeting: 2019 Annual Meeting
Authors: Mauricio Cabezas, MD; Cristian Cartes, MD; Patricia Flores; Fuad Gauro, MD; Claudia Goya; Daniela Lopez; Remigio Lopez-Solís, PhD; Constanza Madrid; Gonzalo Matus; Daniela Salinas Toro; Christian Segovia Cabello; Leonidas Traipe, MD, MSc; Patricio Yañez Baeza; Claudia Zapata
Poster ID: 53571
You must be logged in to view this content

This resource is only available for ASCRS Members. Please log in using the teal "Login" button in the top right-hand corner to log in.

Poster Abstract

Meibomian gland dysfunction (MGD) associated with glaucoma topical treatment (GTT) is related to ocular surface disease (OSD) development. A variety of morphological changes during the natural history of MGD leads finally to glandular atrophy. We purpose to analyze the meibomian gland (MG) morphology differences in patients with different GTT.
A cross-sectional retrospective study was conducted on patients with continuous GTT for at least 6 months. The following groups were established: A= Latanoprost (L) + Timolol (T) + Dorsolamide (D) + Benzalkonium chloride (BAK); B = L + T + BAK; C = T + BAK; D = L + BAK; E = Travoprost + T + Polyquad; Control= Healthy eyes. Meibography was acquired with Keratograph-5M Topographer and analyzed with ImageJ software, obtaining the following morphological glandular parameters: glandular number (GN), glandular tortuosity (GTo), glandular length (GL), glandular thickness (GTh) and meiboscore.
A total of 176 eyes (88 patients) were distributed in groups as the following: A = 30, B = 30, C = 28, D = 30, E = 28, Control = 30. Control group presented the highest GN and GL values. Also, this group had the lowest meiboscore in the superior eyelid (p <0.05). In the inferior eyelid, the best meiboscore was seen in the Control and E groups (p >0.05). Group A presented the shorter GL and meiboscore, but the lowest GTo (p <0.05). Control group presented thinner glands than other therapeutic groups (p <0.05).
The MG morphology differs according to GTT. The type of preservative could play a role in MG toxicity. The GTo may be altered in early stages and would require a minimum GL to be detectable. As OSD decrease both quality of life and patient adherence to treatment, morphological study of MG should be considered in treatment choice and follow-up.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.